Using PET/CT imaging to diagnose alpha-synuclein related diseases
Alpha-Synuclein PET/CT in Various α-Syn-Related Disease
This study is testing three different imaging agents to see if they can help diagnose Parkinson's disease and other related conditions in adults who may have these diseases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 2 sites (Hefei, Anhui and 1 other locations) |
| Trial ID | NCT06949670 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of three different PET/CT imaging agents (18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06) in diagnosing primary and metastatic lesions in patients with alpha-synuclein related diseases, including Parkinson's disease. Participants, who are adults with suspected or newly diagnosed Parkinson's disease, will undergo PET/CT scans to assess the uptake of these imaging agents. The study aims to calculate various diagnostic metrics such as sensitivity, specificity, and accuracy to determine the usefulness of these imaging agents in clinical practice.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 years or older with suspected or newly diagnosed Parkinson's disease.
Not a fit: Patients with non-Parkinson's disease syndromes or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the diagnostic accuracy for patients with alpha-synuclein related diseases, leading to better treatment decisions.
How similar studies have performed: Other studies have explored PET imaging in neurodegenerative diseases, showing promising results, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled α-Syn PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * (i) patients with none PD syndrome; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Hefei, Anhui and 1 other locations
- The First Affiliated Hospital of University of Science and Technology of China — Hefei, Anhui, China (Recruiting)
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (Recruiting)
Study contacts
- Study coordinator: Ying Wang, MD
- Email: macrossplusvoices@163.com
- Phone: +8618702292537
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.